-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Ubrogepant is an oral calcitonin gene-related peptide receptor antagonist used to treat migrainesRecently, researchers compared the efficacy and tolerance of Ubrogepant with a placebo for acute migraine attacksadult patients with migraines or no-precursor migraines participated in the study, with 2 to 8 migraine attacks per month, and were randomly accepted for Ubrogepant 50mg (n-562), Ubrogepant 25mg (n-561) or placebo (n-563)The study's main efficacy endpoint was pain-free and migraine-related symptoms (light phobia, sound phobia and nausea) 2 hours after taking the drug
1,465 patients were treated (average age, 41.5 years; 90% of women) and 1,355 (92.5%) of 1465 people were evaluated for efficacyOf 101 subjects (21.8%) in the 50mg Ubrogepant group, 90 subjects (20.7%) took the 25mg Ubrogepant group, and 65 subjects (14.3%) lost pain after taking a placebo for 2 hours180 people (38.9 per cent) in the 50mg group, 148 people in the Ubrogepant 25 mg group (34.1 per cent) and 125 people in the placebo group (27.4 per cent) reported the symptoms disappear within 2 hoursThe most common adverse events within 48 hours were nausea and dizzinessstudy suggested that taking Ubrogepant significantly increased pain relief by two hours and reduced migraine-related symptoms in adults with migraines compared to placebos
